Caribou Biosciences Q2 results show a better-than-expected loss and slightly higher revenue.

Caribou Biosciences (CRBU) reported Q2 earnings with a better-than-expected loss of $0.42 per share vs. $0.46 estimate, and $3.46M revenue, slightly higher than $3.31M predictions. The company focuses on genome-edited allogeneic cell therapies for hematologic malignancies, with a market cap of $171.60M and a beta of 2.30. Despite negative return on equity and net margin, shares trade at $1.90, with an average "Moderate Buy" rating and $15.00 target price.

August 08, 2024
3 Articles

Further Reading